Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT1 | P54687 | 4/20 | 0.63 |
| ▸ | NHERF1 | O14745 | 5/20 | 0.57 |
| ▸ | GUSB | P08236 | 5/20 | 0.57 |
| ▸ | F7 | P08709 | 1/20 | 0.56 |
| ▸ | F3 | P13726 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | PYGL | P06737 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6399070 | 0.91 | BCAT1 (0.57) | BCAT1NHERF1GUSBF7F3 | |
| SCHEMBL6405094 | 0.87 | GUSB (0.58) | BCAT1NHERF1GUSBF7F3 | |
| SCHEMBL6401177 | 0.85 | KDM4E (0.68) | BCAT1NHERF1GUSBF7F3 | |
| SCHEMBL6401158 | 0.85 | BCAT1 (0.53) | BCAT1NHERF1GUSBF7F3 | |
| SCHEMBL6404723 | 0.84 | NHERF1 (0.62) | BCAT1NHERF1GUSBF7F3 | |
| SCHEMBL6404741 | 0.84 | NHERF1 (0.58) | BCAT1NHERF1GUSBF7F3 | |
| SCHEMBL6398246 | 0.82 | NHERF1 (0.58) | BCAT1NHERF1GUSBF7F3 | |
| SCHEMBL6401059 | 0.82 | BCAT1 (0.59) | BCAT1NHERF1GUSBF7F3 | |
| SCHEMBL6405713 | 0.82 | MAPT (0.70) | BCAT1NHERF1GUSBF7F3 | |
| SCHEMBL6399928 | 0.81 | NHERF1 (0.64) | BCAT1NHERF1GUSBF7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054696-A1 | Indole compounds and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-10 | — | — | US | claimed |
| EP-1452526-A1 | INDOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | claimed |
| US-20050054696-A1 | Indole compounds and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-10 | — | — | US | disclosed |
| EP-1452526-A1 | INDOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054696-A1 | Indole compounds and medicinal use thereof | IDO1, GPR119, SLC5A1 | BCAT1 854/4885NHERF1 332/4885GUSB 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.